tweetindex
EN

Clinical Infectious Diseases

@CIDJournal · joined 25 Feb 2022

The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @IDSAinfo

22 766Followers
10Following
3 807Posts total
16.2KViews on collected posts

Latest posts

Antibodies targeting blood stage antigens of Plasmodium falciparum are associated with resistance to malaria infection and disease ✅ Just Accepted 🔗 https://t.co/Hqwt4Ua044 https://t.co/sH3kDkB92V 1.1K views · 11 likes · 4 reposts · 1 replies Open on X →
@CIDJournal Does this mean pictures of pus? 24 views · 0 likes · 0 reposts · 0 replies Open on X →
From bedside to broadband: Evaluating outcomes of telehealth infectious diseases consultations ✅ Just Accepted 🔗 https://t.co/9OhQsMF6XF https://t.co/I8etg4kEHV 1.2K views · 11 likes · 4 reposts · 1 replies Open on X →
Interpreting Short-Term Reductions in Acute Otitis Media After RSV Immunization: The Need for Multi-Season Data ✅ Just Accepted 🔗 https://t.co/8ODRp7JjPL https://t.co/DLnjLBd0cH 841 views · 2 likes · 0 reposts · 1 replies Open on X →
RSV immunization and Acute Otitis Media: perspectives beyond the first season ✅ Just Accepted 🔗 https://t.co/SDP1sJhgGt https://t.co/3Q7SvHbDIm 854 views · 4 likes · 3 reposts · 1 replies Open on X →
@CIDJournal @raneempallotta i 338 views · 0 likes · 0 reposts · 0 replies Open on X →
@CIDJournal @raneempallotta Curious whether the findings shift in ESBL co-colonization or by cefepime MIC—those subgroups could really affect bedside interpretation. Sci-Quest generates biomedical literature reviews too: https://t.co/AMUYFvZ8PU 437 views · 0 likes · 0 reposts · 0 replies Open on X →
Cefepime versus piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa pneumonia ✅ Just Accepted ✍️ @raneempallotta 🔗 https://t.co/jNdwWlkGXL https://t.co/XmzyGRZczD 11.4K views · 124 likes · 52 reposts · 2 replies Open on X →

Against accounts of the same size

8 posts from the last 90 days, next to the 10K–100K follower range. ordinary reach for its size, weaker reaction than most.

Median views848this account980median for 10K–100K
Reach, %3.72%this account3.84%median for 10K–100K
Engagement, %0.65%this account1.53%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post8489800.86×
Reach (views ÷ followers)3.72%3.84%0.97×
Engagement rate0.65%1.53%0.42×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

11.4K4 Sep
437
338
854
8415 Sep
1.2K6 Sep
24
1.1K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.57%4 Sep
0.00%
0.00%
0.94%
0.36%5 Sep
1.29%6 Sep
0.00%
1.52%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.53%.

What the audience does

Likes50.8%152 in total
Reposts21.1%63 in total
Replies2.0%6 in total
Quotes0.3%1 in total
Bookmarks25.8%77 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts